These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37894533)

  • 21. Spectrophotometric Investigations of Charge Transfer Complexes of Tyrosine Kinase Inhibitors with Iodine as a σ-Electron Acceptor: Application to Development of Universal High-Throughput Microwell Assay for Their Determination in Pharmaceutical Formulations.
    Darwish IA; Darwish HW; Ali AM; Almutairi HS
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109733
    [No Abstract]   [Full Text] [Related]  

  • 22. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].
    Satouchi M; Nishio M; Hida T; Nakagawa K
    Gan To Kagaku Ryoho; 2018 Feb; 45(2):257-264. PubMed ID: 29483416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
    Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A One-Step Green Microwell Spectrophotometric Assay for the Determination of Certain New Chemotherapeutic Drug Formulations.
    Darwish IA; Darwish HW; Alsalhi MS
    J AOAC Int; 2024 Nov; 107(6):903-911. PubMed ID: 38941505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
    J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
    Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
    Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of N-Bromosuccinimide-Water Combination as a Green Reagents for a Validated Indirect Spectrophotometric Determination of Some Antihypertensive Drugs: An Application to Their Monitoring in Marketed Tablets and Capsules.
    Helmy MI; Nessim CK
    J AOAC Int; 2024 Mar; 107(2):226-233. PubMed ID: 38039149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
    Tian W; Zhang P; Yuan Y; Deng XH; Yue R; Ge XZ
    J Clin Pharm Ther; 2020 Aug; 45(4):743-754. PubMed ID: 32369239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dual-function chromogenic and fluorogenic benzofurazan probe for plazomicin and its innovative utility for development of two microwell assays with high throughput for analysis of drug substance and pharmaceutical formulations.
    Alkathiri FA; Al-Outaibi M; Darwish IA
    RSC Adv; 2024 Aug; 14(37):27215-27226. PubMed ID: 39193289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of 4-fluoro-7-nitrobenzofurazan as a dual-function chromogenic and fluorogenic probe for tulathromycin and its innovative utility for development of two eco-friendly and high-through microwell assays for analysis of pharmaceutical formulations.
    Darwish IA; Aljaber KA; Al-Hossaini AM; Alsalhi MS
    Spectrochim Acta A Mol Biomol Spectrosc; 2025 Jan; 325():125079. PubMed ID: 39232308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
    Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
    Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.
    Otoukesh S; Sanchez T; Mirshahidi S; Wallace D; Mirshahidi H
    Cancer Treat Res Commun; 2019; 20():100149. PubMed ID: 31075537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual fluorescence enhancement of loratidine by photoinduced electron transfer blocking and micellization: Application to the development of novel highly sensitive microwell spectrofluorimetric assay for analysis of dosage forms and urine samples.
    Darwish IA; Alzoman NZ
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jan; 305():123458. PubMed ID: 37816264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charge-transfer reaction of 2,3-dichloro-1,4-naphthoquinone with crizotinib: Spectrophotometric study, computational molecular modeling and use in development of microwell assay for crizotinib.
    Alzoman NZ; Alshehri JM; Darwish IA; Khalil NY; Abdel-Rahman HM
    Saudi Pharm J; 2015 Jan; 23(1):75-84. PubMed ID: 25685046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.